Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000189794 | SCV000243442 | uncertain significance | not provided | 2018-11-15 | criteria provided, single submitter | clinical testing | A variant of uncertain significance has been identified in the TPP1 gene. The L515F variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The L515F variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, this substitution occurs at a position that is conserved across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Labcorp Genetics |
RCV000189794 | SCV001384407 | likely benign | not provided | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002399705 | SCV002705094 | uncertain significance | Inborn genetic diseases | 2024-10-28 | criteria provided, single submitter | clinical testing | The c.1543C>T (p.L515F) alteration is located in exon 12 (coding exon 12) of the TPP1 gene. This alteration results from a C to T substitution at nucleotide position 1543, causing the leucine (L) at amino acid position 515 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001274536 | SCV001458783 | uncertain significance | Neuronal ceroid lipofuscinosis 2 | 2020-04-14 | no assertion criteria provided | clinical testing |